Cell Lysis & Disruption Market Size & Share 2024 to 2032

Cell Lysis & Disruption Market Size

Cell Lysis & Disruption Market size was valued USD 5.1 billion in 2023 and is expected to reach USD 10.9 billion by 2032 growing at a CAGR of 8.6% over the analysis period. High growth can be attributed to the expanding biopharmaceutical industry that relies on cell lysis and disruption techniques to produce therapeutic proteins, monoclonal antibodies, and vaccines.

Also, the growing interest in precision medicine and advancements in genomics research has further increased the demand for cell lysis and disruption technologies. Moreover, growing investments by several organizations, including government and private, towards the research and development related to biotechnological processes are further expected to drive the market. Thus, as the life sciences industry continues to evolve, the cell lysis and disruption market are expected to witness sustained growth.
 

Cell lysis and disruption refer to the process of breaking open or disrupting the cell membrane of biological cells, releasing the cellular contents. This is a crucial step in various biological and biochemical applications, such as protein purification & isolation, DNA or RNA isolation, and the production of cellular products.
 

COVID-19 Impact

The COVID-19 pandemic had a positive impact on market progress. An increase in research and development activities for developing a vaccine for COVID-19 augmented the demand for technologies used for bioprocessing, including cell lysis & disruption. The severe respiratory effects of the virus created an urgent demand for innovative treatments, leading to further medication discoveries and favourable effects on the cell lysis industry.
 

Cell Lysis & Disruption Market Trends

• As the pharmaceutical industry continues to witness unprecedented growth in the development of biologically derived drugs, the demand for efficient cell lysis and disruption technologies is expected to escalate. These techniques are integral in extracting valuable cellular components, such as proteins, enzymes, and nucleic acids, to produce biopharmaceuticals. Thus, surge in biopharmaceutical research has emerged as a potent catalyst propelling the cell lysis and disruption market forward.
   
• Further, the continuous expansion of biologics and personalized medicine has increased the demand for innovative and high-throughput cell lysis methods to facilitate the isolation of target biomolecules. For instance, in 2014, personalized medicines accounted for only 21% of the total FDA approved new molecular entities, while in 2022 they accounted for 34% of approved new molecular entities.
   
• Thus, the demand for precise and efficient cell lysis methods has surged, driven by the need to obtain high-quality biomolecules for personalized diagnostics, drug development, and therapy monitoring.
   

However, the acquisition and maintenance costs associated with cutting-edge cell lysis equipment may be prohibitive for many laboratories and organizations, particularly those with limited budgets. This factor of high costs may pose a challenge for market growth.
 

Cell Lysis & Disruption Market Analysis

Based on technique, the cell lysis and disruption market is segmented into reagent-based and physical disruption. The reagent-based segment is further categorised into detergent and enzymatic. The reagent-based segment is expected to lead the market, projecting revenue of USD 5.9 billion by 2032.
 

• Reagent-based methods offer a simplified and user-friendly approach, eliminating the need for complex equipment and specialized skills. This accessibility makes these techniques attractive to a broader range of researchers, including those with limited laboratory resources.
   
• Also, reagent-based cell lysis is often more cost-effective compared to alternative mechanical or physical disruption methods, as it avoids the investment in expensive machinery.
   
• Moreover, reagents can be tailored to specific cell types and applications, providing researchers with a high degree of customization and flexibility.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on product, the cell lysis & disruption market is classified into instruments and reagents & consumables. The reagents & consumables segment dominated the market in 2023 and is anticipated to grow at a CAGR of 8.4% between 2024 – 2032.
 

• The escalating demand for advanced technologies in molecular biology and biotechnology research has propelled the need for efficient cell lysis and disruption methods, thereby driving the consumption of reagents and consumables.
   
• Also, researchers and scientists are increasingly relying on innovative products within this segment to achieve optimal results in cellular analysis, protein extraction, and nucleic acid isolation. Thus, the robust growth can be attributed to the continual development of cutting-edge reagents and consumables, characterized by enhanced performance, ease of use, and compatibility with diverse sample types.
   

Based on cell type, the cell lysis & disruption market is classified into mammalian cells, microbial cells, and other cell types. The mammalian cells segment dominated the market accounting for the largest revenue of USD 2.4 billion in 2023.
 

• Mammalian cells, owing to their complex and physiologically relevant structures, are extensively employed in various applications, including protein expression, cell-based assays, and vaccine production. Therefore, researchers and industry professionals prefer mammalian cells for their ability to mimic human cellular functions accurately, making them indispensable in drug development and therapeutic research.
   
• Additionally, these cells serve as preferred hosts for the expression of complex proteins that are challenging to produce in bacterial or yeast cells. All these factors together contribute to the high segment share.
   

Based on application, the cell lysis & disruption market is classified into protein isolation, nucleic acid isolation, and other applications. The protein isolation segment dominated the market accounting for 47.3% business share in 2023.
 

• Cell lysis & disruption is a widely used method for isolation of a diverse range of proteins from different cell types. Researchers and biopharmaceutical companies rely on efficient protein isolation due to its wide applications in proteomics, personalized medicine, drug discovery, and therapeutics development.
   
• Technological innovations, such as the development of novel cell lysis methods and disruptive technologies, have played a pivotal role in enhancing the efficiency and scalability of protein isolation processes, thereby driving the segment progress.
   

Based on end-use, the cell lysis and disruption market is classified into pharmaceutical and biotechnology companies, academic and research institutes, and other end-users. The pharmaceutical and biotechnology companies segment dominated the market in 2023.
 

• Pharmaceutical and biotechnology companies are increasingly relying on cell lysis and disruption techniques to extract intracellular contents efficiently, facilitating the isolation of valuable biomolecules such as proteins, nucleic acids, and organelles.
   
• Additionally, the continuous development of novel drugs and biologics has further propelled the adoption of cutting-edge cell disruption methods by pharma and biotech companies, thereby making them prominent end-users of this technology.
   

 In 2023, North America held a significant market share of 37.9% in the global cell lysis & disruption market and is anticipated to dominate the market throughout the forecast period.
 

• The region's dominance can be attributed to a robust infrastructure supporting cutting-edge research and development, a thriving biotechnology industry, and a well-established healthcare ecosystem. Also, the presence of leading market players, state-of-the-art laboratories, and a high level of technological innovation further contribute to North America's remarkable market share.
   
• Additionally, the region benefits from a strong focus on biopharmaceuticals, biotechnology, and life sciences, with a supportive regulatory environment that fosters advancements in cell lysis and disruption technologies.
   

Cell Lysis & Disruption Market Share

The cell lysis and disruption industry is characterized by diverse players competing in the industry, leveraging their research capabilities and global presence. Strategic collaborations, product innovations, and regulatory compliance further strengthen their positions. Also, the market is characterized by ongoing technological advancements and a focus on developing safer and more effective products, further intensifying the competitive dynamics in the healthcare sector.
 

Cell Lysis & Disruption Market Companies

Prominent players operating in the cell lysis and disruption industry is as mentioned below:

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN N.V.
• Danaher Corporation
• Miltenyi Biotec
• Claremont BioSolutions, LLC
• IDEX
• Parr Instrument Company
• Covaris, LLC
• Cell Signaling Technology, Inc.
• Qsonica
   

Cell Lysis & Disruption Industry News:

• In July 2023, Qiagen N.V. launched its new CGT viral vector lysis kit that enables a standardized workflow from cell lysates to absolute and precise quantification of viral titters for multiple serotypes. This strategy is expected to help the company to expand its product offerings.
   
• In January 2021, Thermo Fisher Scientific, Inc. acquired Henogen S.A., the viral vector manufacturing business of Novasep. This expanded the company's capabilities for gene and cell therapies & vaccines and enhanced its cell lysis and disruption business as part of the manufacturing workflow.
   

The cell lysis & disruption market research report include an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Technique, 2018 – 2032 (USD Million)

• Reagent-based
  • Enzymatic
  • Detergent 
• Physical disruption
  • Mechanical
  • Ultrasonic
  • Pressure
  • Temperature

By Product, 2018 – 2032 (USD Million)

• Reagents & consumables
  • Enzymes
  • Detergent solutions
  • Kits & reagents 
• Instruments
  • Homogenizers
  • Sonicator
  • Microfluidizer
  • Other instruments

By Cell Type, 2018 – 2032 (USD Million)

• Mammalian cell
• Microbial cell
• Other cell types

By Application, 2018 – 2032 (USD Million)

• Protein isolation
• Nucleic acid isolation
• Other applications

By End-use, 2018 – 2032 (USD Million)

• Pharmaceutical and biotechnology companies
• Academic and research institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa